A Phase 4 interventional study of GV-971 and Placebo in Alzheimer's Disease, sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd.. Recruiting at 50 sites in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-11-09.
Sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.
Among the 260 studies in Alzheimer Disease with a site in China, this one is the 12th largest by planned enrollment of the 176 interventional ones that give a count, is one of 21 that started in 2023, is one of 11 in phase 4, reaches primary completion later than 135 of the 161 other live ones, and was the 113th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
Hoffmann-La Roche · Sites in China, United States, Argentina and 7 more countries
Ages 55–80
Eli Lilly and Company · Sites in China, United States, Japan
Ages 18–85 · Healthy volunteers
Anhui Medical University · Sites in China
Ages 45–84
JYAMS PET Research & Development Limited · Sites in China
Ages 50+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
260 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 28 · Phase 3 36 · Phase 4 11
First in 2000; this study’s year is marked. 21 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,312 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 100 across the 176 interventional studies, 566 across the 84 observational. Of the 65 that completed or were terminated, 16 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 260 have an industry lead sponsor. The 10 most frequent:
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. has 4 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
44 of the studies in Alzheimer Disease with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT07422857Phase 3JYAMS PET Research & Development LimitedEvaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function | 2026-12-01 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07323914Phase 3Xuanwu Hospital, BeijingClinical Analgesic Management in Dementia | 2027-01-01 |
Add all 44 to your calendar (.ics) → With an account.
Among the 260 studies in Alzheimer Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more guidance for clinical use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GV-971
Drug: Placebo
Administered PO
Administered PO
Change from baseline in the ADAS-cog/12 score
Change from baseline in Alzheimer's Disease Assessments Scale - cognitive (ADAS-cog/12) scale total score. The total score of ADAS-cog/12 is 0-75, with higher scores mean a worse outcome.
Time frame: Baseline, 36 weeks
Change from baseline in ADCS-ADL23 score
Change from baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living-23-item Scale (ADCS-ADL23) score in moderate AD participants. The total score of ADCS-ADL23 is 0-78, with higher scores mean a better outcome.
Time frame: Baseline, 36 weeks
Change from baseline in MMSE score
Change from baseline in Mini-Mental State Examination (MMSE) score. The total score of MMSE is 0-30, with higher scores mean a better outcome.
Time frame: Baseline, 36 weeks
Change from baseline in the CIBIC-Plus score
Change from baseline on Clinician's Interview-Based Impression of Change Plus (CIBIC-Plus) scale total score. The total score of CIBIC-Plus is 1-7, with higher scores mean a worse outcome.
Time frame: Baseline, 36 weeks
Change from baseline in NPI score
Change from baseline in Neuropsychiatric Inventory (NPI) score. The total score of NPI is 0-144, with higher scores mean a worse outcome.
Time frame: Baseline, 36 weeks
Change from baseline in ADCS-ADL23 score
Change from baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living-23-item Scale (ADCS-ADL23) score. The total score of ADCS-ADL23 is 0-78, with higher scores mean a better outcome.
Time frame: Baseline, 36 weeks
Change from baseline on A-beta protein of CSF
Change from baseline on biomarkers of CSF A-beta protein after 36 weeks of treatment.
Time frame: Baseline, 36 weeks
Change from baseline on Tau protein of CSF
Change from baseline on biomarkers of CSF Tau protein after 36 weeks of treatment.
Time frame: Baseline, 36 weeks
Change from baseline on biomarkers of Th1/Th2 cell subtypes
Change from baseline on biomarkers of peripheral blood immune cell subtypes of Th1/Th2 after 36 weeks of treatment.
Time frame: Baseline, 36 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Jun 2029, 70 months after the start.
Of 41 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 70 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GV-971
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.